Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Hiatt

Showing results (31-40 of 232) with videos related to

Pageof 24
Sort By:
Circulation|September 8, 2016
Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular DeathBrendan M Everett, William R Hiatt
Clinical Cornerstone|November 12, 2002
Treatment of peripheral arterial diseaseJudith G Regensteiner, William R Hiatt
European Heart Journal|February 1, 2020
Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step backConnie N Hess, William R Hiatt
Journal of the American College of Cardiology|June 11, 2016
The Development of Therapeutics for Peripheral Artery Disease: A Unique Cardiovascular Risk PopulationWilliam R Hiatt, R Kevin Rogers
The New England Journal of Medicine|January 31, 2014
Assessing the clinical benefits of lipid-disorder drugsWilliam R Hiatt, Robert J Smith
Circulation|July 25, 2012
Medical therapy in peripheral artery diseaseJeffrey S Berger, William R Hiatt
The Cochrane Database of Systematic Reviews|July 5, 2013
Omega-3 fatty acids for intermittent claudicationAndrew Campbell, Jackie Price, William R Hiatt
JAMA|September 20, 2012
Cardiovascular risk assessment in the development of new drugs for obesityWilliam R Hiatt, Allison B Goldfine, Sanjay Kaul
Vascular Medicine (London, England)|February 1, 2005
Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussionEric P Brass, William R Hiatt, Simon Green
Cardiovascular Diagnosis and Therapy|November 28, 2013
Aspirin in primary prevention: can we individualize care?Anuradha Lala, William R Hiatt, Jeffrey S Berger
Pageof 24

Showing results (31-40 of 232) with videos related to

Sort By:
Pageof 24
Circulation|September 8, 2016
Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular DeathBrendan M Everett, William R Hiatt
Clinical Cornerstone|November 12, 2002
Treatment of peripheral arterial diseaseJudith G Regensteiner, William R Hiatt
European Heart Journal|February 1, 2020
Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step backConnie N Hess, William R Hiatt
Journal of the American College of Cardiology|June 11, 2016
The Development of Therapeutics for Peripheral Artery Disease: A Unique Cardiovascular Risk PopulationWilliam R Hiatt, R Kevin Rogers
The New England Journal of Medicine|January 31, 2014
Assessing the clinical benefits of lipid-disorder drugsWilliam R Hiatt, Robert J Smith
Circulation|July 25, 2012
Medical therapy in peripheral artery diseaseJeffrey S Berger, William R Hiatt
The Cochrane Database of Systematic Reviews|July 5, 2013
Omega-3 fatty acids for intermittent claudicationAndrew Campbell, Jackie Price, William R Hiatt
JAMA|September 20, 2012
Cardiovascular risk assessment in the development of new drugs for obesityWilliam R Hiatt, Allison B Goldfine, Sanjay Kaul
Vascular Medicine (London, England)|February 1, 2005
Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussionEric P Brass, William R Hiatt, Simon Green
Cardiovascular Diagnosis and Therapy|November 28, 2013
Aspirin in primary prevention: can we individualize care?Anuradha Lala, William R Hiatt, Jeffrey S Berger
Pageof 24